Novo Nordisk’s Q2 Profits Slim Down as Competition Bulks Up
The pharmaceutical industry leader behind the popular weight loss drug Wegovy has a tough pill to swallow. Novo Nordisk reported disappointing Q2 earnings that fell ~4% short of Wall Street’s expectations. As competition in the weight loss sector beefs up, trimmed its earnings outlook, prompting a sharp 8% drop in trading yesterday.
- reduced its operating profit forecast to 20% to 28%, down from 22% to 30% — citing “supply constraints” and rebate challenges with pharmacy benefit managers.
- Rivals are capitalizing on the weight loss drug shortages — Eli Lilly’s Zepbound has already captured ~40% of the US market, while Roche sees promising early-stage trial results.
The weight of growth: With Wegovy sales surging 363% in the first six months of 2023, Novo Nordisk has learned to balance demand with production constraints. Hungry for market share, the company announced an $11B acquisition of manufacturing sites from Catalent to boost production for 2026 and has received approval for a China launch. In this high-stakes weight loss world, Novo Nordisk is determined to maintain its heavyweight status.
